Get Email Alerts
NIH State of the Science Symposium on Myelodysplastic Syndromes (MDS)
Receive email updates about meeting announcements. Learn more.
|
NIH State of the Science Symposium on Myelodysplastic Syndromes (MDS)
Agenda
Wednesday, September 7, 2011
| 7:00 - 5:00 p.m. | Registration |
|---|---|
| 8:00 a.m. | Introductions and Opening Remarks |
| Susan B. Shurin, M.D. Acting Director, NHLBI Hal E. Broxmeyer, Ph.D. Indiana University School of Medicine | |
| 8:20 a.m. | Plenary Talk MDS: What Have We Achieved in the Last Ten Years? Pierre Fenaux, M.D., Ph.D. Höpital Avicenne University (France) |
| 8:50 a.m. | Session I: Scientific and Clinical Challenges |
| Overview and Scientific Challenges and Questions Cheryl L. Willman, M.D University of New Mexico Cancer Research and Treatment Center Prognostic and Predictive Markers of Tomorrow Eva Hellstrom-Lindberg, M.D., Ph.D. Karolinska Institutet (Sweden) Clinical Challenges and Questions Guillermo Garcia-Manero, M.D. MD Anderson Cancer Center | |
| Roundtable Discussion Break | |
| 11:00 a.m. | Session II: Biology and Pathophysiology Overview Benjamin L. Ebert, M.D., Ph.D. Brigham and Women's Hospital Microenvironment in the Regulation of Normal and MDS Stem Cells David T. Scadden, M.D. Massachusetts General Hospital / Harvard Stem Cell Institute Genetic Lesions that Phenocopy Dysplasia and Progression to AML Peter D. Aplan, M.D. National Cancer Institute Bone Marrow Failure Syndromes and MDS Monica Bessler, M.D., Ph.D. University of Pennsylvania Roundtable Discussion |
| 12:45 p.m. | Lunch |
| 1:30 p.m. | Session III: MDS Genomics Overview Timothy Graubert, M.D. Washington University in St. Louis Inherited Predisposition to MDS: Syndromic, Familial, and Sporadic Mutations Marshall S. Horwitz, M.D., Ph.D. University of Washington Mutation Discovery in MDS Using Next-generation Sequencing Mathew J. Walter, M.D. Washington University in St. Louis Biological Consequences of Mutations in the 5q Commonly Deleted Interval Benjamin L. Ebert, M.D., Ph.D. Brigham and Women's Hospital Roundtable Discussion Break |
| 3:35 p.m. | Session IV: MDS Epigenomics Overview Jaroslaw P. Maciejewski, M.D., Ph.D. Cleveland Clinic MDS Methylome and Array-based Screens Ari M. Melnick, M.D. Weill Cornell Medical College Genetic Drivers of Aberrant DNA Methylation and Demethylation in MDS Jaroslaw P. Maciejewski, M.D., Ph.D. Cleveland Clinic Characterization of Abnormal Histone Modification and Genetic Drivers in MDS James G. Herman, M.D. John Hopkins University Roundtable Discussion |
| 6:00 p.m. | Adjourn |
Thursday, September 8, 2011
| 8:00 - 9:30 a.m. | Session V: Improved Therapeutic Outcomes Overview Eva Hellstrom-Lindberg, M.D., Ph.D. Karolinska Institutet (Sweden) MDS Stem Cells and Therapies: Enhancing Cure Rate-biomarkers for Resistant Disease and Risk of Relapse Sten Erik W. Jacobsen, M.D., Ph.D. University of Oxford (UNITED KINGDOM) High Risk Disease and Relapse: Prospects of Epigenetic Therapy Steven D. Gore, M.D. Johns Hopkins University Low-risk MDS and Anemia: Biomarkers for Selecting Optimal Treatment for Cytopenia Stephen D. Nimer, M.D. Memorial Sloan-Kettering Cancer Center Roundtable Discussion |
|---|---|
| Session VI: Summary and Discussion Pierre Fenaux, M.D., Ph.D. Hôpital Avicenne University (France) Hal E. Broxmeyer, Ph.D. Indiana School of Medicine | |
| Noon | Adjournment |
Twitter
Facebook
YouTube
Google+